Back to Online Symposia Home Page
|
|
Program Description
Current data indicate that schizophrenia continues to be a highly prevalent disorder, with high relapse rates. Patients with schizophrenia continue to suffer both on a personal and societal level. Their quality of life remains poor and the high relapse rates dramatically impact both direct and indirect healthcare costs. Even though new therapies continue to emerge, adverse effects of medications continue to challenge physicians. Furthermore, studies indicate that a large percentage of patients remain nonadherent with their therapies due to both partial response to therapy as well as to the occurrence of side effects.
Learning Objectives
By participating in this activity, you will be able to:
- Explain the prevalence and economic burden of schizophrenia
- Understand the mechanism of action, pharmacodynamics/kinetics and how receptor binding profiles can be used to predict safety
- Evaluate the efficacy and safety profiles of current and emerging therapies for the treatment of schizophrenia and assess how clinicians can apply this information to improve adherence rates
Who Will Benefit
This activity was designed to meet the continuing education needs of psychiatrists and other physicians, physician assistants, registered nurses, psychiatric nurses and advanced practice nurses. Other mental health professionals may find this activity informative and should check with their state licensing and certification boards to determine if it meets their continuing education requirements.
Your Distinguished Faculty
Schizophrenia Treatments: Pharmacodynamics/Kinetics and Receptor Binding Profiles
James C.-Y. Chou, MD
Associate Professor, Mt. Sinai School of Medicine
Faculty Disclosures
James C.-Y. Chou, MD, has been a member of the Speakers Bureau and has received honoraria from AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline, and Janssen, L.P. He receives grants and/or research support from Bristol-Myers Squibb Company, GlaxoSmithKline, and Janssen, L.P. Dr. Chou is also on the Speakers Bureau for Pfizer Inc. and Abbott.
Current and Emerging Therapies: Efficacy, Safety and Adherence
David C. Henderson, MD
Associate Professor of Psychiatry, Harvard
Associate Director of Schizophrenia Program, Massachusetts General Hospital
Faculty Disclosures
David C. Henderson, MD, has received grant/research support and/or honoraria from Pfizer Inc., Bristol-Myers Squibb Company,
and Eli Lilly and Company. He has also acted as a consultant for Bristol-Myers Squibb Company, Wyeth Pharmaceuticals,
Solvay Pharmaceuticals Inc., Otsuka America Pharmaceutical, Inc., and Pfizer Inc. In addition, Dr. Henderson has also received honoraria from Solvay and Wyeth Pharmaceuticals.
|
Commercial Support
 
Supported in part by an unrestricted educational grant from Solvay and Wyeth Pharmaceuticals
Disclaimers
The content of this video activity may include product information that is inconsistent with or outside of the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer's product information.
To earn continuing education credit, view this online course and complete the posttest and evaluation provided. A passing score of 70% or more must be achieved on the posttest. A link is provided within this online activity to access the posttest and evaluation. You will have the option of printing a Statement of Credit for your records after submission of the evaluation.
CME LLC, Solvay and Wyeth Pharmaceuticals are not responsible for the speaker's statements, materials, acts or omissions. |
|
Continuing Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME credits from activities presented by ACCME accredited providers may be used toward American Osteopathic Association (AOA) Category 2-A requirements.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.0 contact hour for nurses.
The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ toward recertification requirements.
Content Originally Presented: October 10, 2007
Online Date: December 17, 2007
Credit Expiration Date: December 16, 2008
This activity is based on the symposium Targeting Novel Therapies in Schizophrenia: Considerations for Physicians and Patients at the 20th Annual U.S Psychiatric and Mental Health Congress in October, 2007 in Orlando, Fla. Participants who attended the live symposium mentioned above cannot claim credit for this activity.
|
